IMPORTANCE Hand-foot syndrome (HFS) is a common adverse effect of capecitabine treatment.
H and-foot syndrome (HFS), also known as palmoplantar erythrodysesthesia, is a common adverse effect of the fluoropyrimidine chemotherapy agent capecitabine. Hand-foot syndrome of any grade is reported to affect 43% to 71% of patients treated with single-agent capecitabine chemotherapy. [1] [2] [3] [4] Although not life-threatening, it can have adverse effects on the quality of life (QoL) and daily living activities of a patient. The dose interruptions and reductions required after observation of HFS can also impact on dose intensity and treatment outcomes. Despite its common occurrence, the pathophysiology of HFS is not well understood. At the time of conception of this study, pyridoxine (vitamin B6) was commonly used by clinicians to prevent and/or treat HFS with capecitabine. This was based on similarity to acrodynia caused by pyridoxine deficiency in rats, anecdotal reports, and retrospective series on the effectiveness of pyridoxine in ameliorating HFS associated with fluorouracil (5-FU) and capecitabine.
5-7 Although a trial on patients with gastrointestinal tract malignancies receiving capecitabine either as single agent or in combination with cisplatin with or without docetaxel has since reported the ineffectiveness of pyridoxine 200 mg daily in preventing HFS, 8 pathophysiologic biomarkers predictive of HFS were not evaluated. Accumulating data suggests that there are regional differences in the tolerability of fluoropyrimidines, with many reports indicating that East Asian patients experience a lower incidence of serious toxic effects when treated with 5-FU-based or capecitabine-based regimens compared with white patients.
9-11 Dietary folate intake and pharmacogenomics have been highlighted as possible contributors to these disparities. This randomized, double-blind phase 3 trial was designed to evaluate the efficacy of pyridoxine at preventing HFS in patients receiving capecitabine single-agent chemotherapy as a primary objective, given the potential for combination treatment to confound the assessment of HFS. To elucidate the predictors of HFS further, biomarker analyses including folate and vitamin B12 levels and genome-wide analyses were performed to explore predictors of capecitabineinduced HFS. To our knowledge, this is the first genomewide association study (GWAS) of capecitabine-induced HFS conducted in an Asian population.
Methods

Study Design
This single-center, randomized double-blind, placebocontrolled phase 3 trial conducted at National Cancer Centre Singapore assessed whether oral pyridoxine could prevent the onset of grade 2 or higher HFS in patients scheduled to receive single-agent capecitabine chemotherapy for any malignancy, either in the neoadjuvant, adjuvant, or palliative setting. Exclusion criteria included the intake of concomitant drugs known to induce HFS or neuropathy, drugs known to interact with pyridoxine, concurrent pyridoxine-containing preparations, use of urea-containing or lactic acid-containing topical creams or lotions, previous treatment with capecitabine, and/or known hypersensitivity to pyridoxine. Each patient provided written informed consent prior to study entry. The study protocol was approved by the Singapore Health Services (SingHealth) institutional review board (Supplement 1).
The primary objective was incidence of grade 2 or higher HFS; secondary objectives included time from study commencement to first occurrence of grade 2 or higher HFS, healthrelated QoL and analysis of biomarkers predictive of HFS. Based on literature review, the overall incidence of grade 2 or higher HFS for capecitabine monotherapy was estimated to be 36% to 40%. To demonstrate a reduction in incidence of grade 2 or higher HFS from 36% to 20% with α = .05 and power of 80%, a requirement of 123 patients per group, or 246 patients in total, was determined. Up to 20% of patients were anticipated to discontinue capecitabine before the fourth cycle of therapy and affect the evaluation of HFS, hence target accrual was set at 296 patients, corresponding to an increase in sample size of 25 patients (approximately 20%) per group. However, the trial was terminated before reaching the original target of 296 patients due to slow accrual associated with the declining use of singleagent capecitabine, especially for gastrointestinal cancers.
Treatment Administration
Patients were stratified by sex and treatment setting (adjuvant or neoadjuvant vs palliative), and randomized to receive either pyridoxine (200 mg/d) or placebo in a 1:1 ratio for a maximum of 8 cycles of capecitabine. The minimum starting dose for the first 59 patients was 800 mg/m 2 or more twice daily for the first 2 weeks (rounded up or down to the closest dose comprising 150 mg and 500 mg tablets) on a 3-weekly cycle. The protocol was subsequently amended to stipulate a minimum starting dose of 1000 mg/m 2 or more twice daily due to increasing evidence of better tolerability in Asian patients, 9 in addition to the inclusion of baseline folate and vitamin B12 levels for biomarker analyses. Patients were withdrawn from the study on occurrence of grade 2 or higher HFS or capecitabine discontinuation, for example, owing to unacceptable toxic effects or evidence of progressive disease, whichever occurred earlier.
changes or dermatitis without pain; grade 2, if skin changes (eg, bleeding, blisters, peeling, edema) or pain not interfering with function was present; and grade 3, if there was ulcerative dermatitis or skin changes with pain interfering with function. While patients were given a diary for symptoms of HFS to help the physician with documenting the onset and severity of HFS, the toxic effects were graded by the treating physician for assessment of the primary end point, as well as other adverse events.
Patients who developed HFS of grade 2 or greater severity would be withdrawn from the study, and institution of daily pyridoxine with or without dose reduction of capecitabine could subsequently occur at the clinician's discretion. Patients who developed grade 1 HFS could be treated with topical emollients if deemed necessary by the treating oncologist, but dose interruption or reduction for grade 1 HFS was not permitted. Interruption, delay, or modification of dose of capecitabine for other toxic effects was permitted based on the discretion of the treating clinician.
Assessment of QoL
Quality of life was assessed using the EuroQol EQ-5D-3L questionnaire 12 (version 5.0) at baseline, the start of cycles 2, 4, 6, and 8, as well as at the end of the study or after treatment discontinuation.
Assessment of Biomarkers
Blood samples were collected at baseline from patients who consented for biomarker analyses. In addition to testing of red blood cell folate, serum folate, and vitamin B12, DNA was extracted using the EZ1 Advanced automated nucleic acid extractor (Qiagen). Genotyping of the DNA for more than 890 000 markers within East Asia populations was performed using HumanOmniZhongHua-8 BeadChips (Illumina). Phasing was performed using SHAPEIT, while imputation was performed with IMPUTE2 using the cosmopolitan 1000 Genomes Phase 1 integrated haplotypes panel (December 2013 release) as a reference. Variants with a call rate less than 0.95 and those that deviated from HardyWeinberg equilibrium (HWE) (P <10 −5 ) were excluded from analysis. Checks were also performed for population outliers against the HapMap3 database, and cohort outliers using smartpca in EIGENSOFT. SNPTEST was used for logistic regression analysis based on an additive genetic model. To control for potential population stratification and other confounders, analyses were adjusted for race, age, sex, and capecitabine dose. Statistical significance was inferred at the genome-wide threshold of P <5×10 −8 .
Statistical Analyses
Primary efficacy analysis was based on the intent-to-treat population, which included all randomly assigned patients. The incidence of grade 2 or higher HFS was compared using a χ 2 test; time to onset was estimated using the Kaplan-Meier method and compared using a log-rank test, and QoL was analyzed using ANOVA for the EQ-5D OHS and χ 2 tests for each of the 5 dimensions of the EQ descriptive system. Logistic regression was used to estimate the odds of HFS (grade ≥2 vs <2) with respect to clinical characteristics. The exact procedure was used when quasiseparation was detected. All covariates were included in multivariate analysis with a stepwise selection process using significance levels of 0.1. Interaction between treatment and covariates suggested by the stepwise procedure was explored. Alternative models were assessed in terms of discrimination and calibration respectively using the c-index and the Akaike Information criterion (AIC). The Statistical Analysis System version 9.4 (SAS Institute Inc) was used for analysis. A P value of less than .05 was considered statistically significant.
Results
Patients
Between June 2007 and May 2014, 210 patients starting capecitabine were enrolled and randomized to pyridoxine or placebo (Figure) . Baseline demographic and clinical characteristics were well balanced between the 2 arms (Table 1) . Overall, 44 patients (21.0%) received treatment in the neoadjuvant or adjuvant setting, while 166 patients (79.0%) received treatment on a palliative basis. The majority of the patients had metastatic breast cancer (n = 138 [66%]); 144 patients (67.6%) received prior chemotherapy, with a median (range) of 2 (0-9) regimens. Table 2 ). There were no significant differences in the severity and incidence of other drug-related ad- Figure. CONSORT Diagram verse events (eTable 1 in Supplement 2). Capecitabine was well tolerated overall, with less than 2% of patients experiencing grade 3 diarrhea. The maximum severity of vomiting and stomatitis was grade 2, reported in 6 patients (2.9%) and 2 patients (1.0%), respectively. The median time until grade 2 or higher HFS was not reached in both arms, with no difference between the 2 arms (P = .73; eFigure 1 in Supplement 2). The incidence of grade 2 or higher HFS was 15.4% (95% CI, 8.2%-22.7%) and 13.7% (95% CI, 6.7%-20.6%) for the placebo and pyridoxine group, respectively, at 60 days, and 41.0% (95% CI, 30.3%-51.8%) and 36.9% (95% CI, 25.7%-48.1%), respectively, at 120 days.
Efficacy of Pyridoxine for HFS Prophylaxis
Efficacy of Pyridoxine for QoL Outcomes
Analysis of the EuroQol EQ-5D-3L questionnaire revealed no significant differences between each of the 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/ depression) or the overall health status at any time point (eFigure2inSupplement 2).
Association of HFS With Clinical Variables
In univariate analysis, serum folate, red blood cell folate, and starting capecitabine dosage were significant predictors of grade 2 or higher HFS (Table 3) . For multivariate analysis, it was noted that serum folate and red blood cell folate were In addition, the data from a manually curated list of genes previously reported to be associated with fluoropyrimidine toxic effect (namely CDA, CES2, DPYD, MIR27A, MTHFR, TYMP, TYMS, and UMPS) 21 were inspected for their association with grade 2 or higher HFS. Of these, an association with grade 2 or higher HFS was observed for a novel DPYD variant (rs75267292 [P <1.57×10 −10 ]).
Discussion
To date, there do not appear to be any effective therapies for the prevention of capecitabine-related HFS. ported that the addition of celecoxib led to significant reductions in HFS, the majority of the 150 patients with colorectal cancer in this randomized study received capecitabine with oxaliplatin, which can confound the assessment of HFS from capecitabine. Differences in dietary folate intake has been suggested as a possible explanation for the lower incidence of toxic effects from fluoropyrimidines in patients of East Asian origin. 9 After conversion of capecitabine to fluorouracil by the sequential actions of carboxylesterase, cytidine deaminase, and thymidine phosphorylase, binding of the active fluorouracil metabolite fluorodeoxyuridine monophosphate (FdUMP) to thymidylate synthase (TS) is stable only in the presence of folate. 27 Increased levels of exogenous folate could hence potentially lead to enhanced TS inhibition and toxic effects. Clinical evidence of the association between dietary folate and toxic effects from fluoropyrimidines is limited to a phase 2 study of fixed-dose capecitabine in patients with advanced colorectal cancer that reported increased toxic effects with higher pretreatment serum folate in 36 patients. 28 In support, the risk of grade 2 or higher HFS positively correlated with levels of serum folate, as well as red blood cell folate, in multivariate analysis in this study. Serum folate reflects the immediate folate pool and varies with dietary intake, while red blood cell folate is indicative of folate body stores and the folate turnover over the preceding 3 to 4 months and is not subject to short-term fluctuation. From these results, it is tempting to speculate that lower folate levels could be a factor in the better tolerance of East Asians to capecitabine. Nonetheless, only 1 in 150 patients in the current study had red blood cell folate levels less than 283 nmol/L, suggesting that true folate deficiency is uncommon in our population. Studies comparing folate levels of patients receiving capecitabine from different regions would help to investigate this further. Although the variability in starting dose of capecitabine may be one of the limitations of this study, this allows us to study the correlation of HFS toxic effects with dose, and we found a nonsignificant trend on multivariate analysis. This is a reflection of real-world clinical practice, to which the findings of our study may be applied, and both our multivariate and GWAS analyses also corrected for the variability in dose. Although the US Food and Drug Administration approved dose of capecitabine is 1250 mg/m 2 twice daily for 14 out of 21 days, lower doses are often prescribed, as postmarketing experience revealed significant toxic effects at the registered dose. 29 Studies evaluating capecitabine at a starting dose of 1000 mg/m 2 twice daily for 14 out of 21 days suggest similar efficacy to the higher approved dose. 29-32 I nf a ct ,i ti sn o t uncommon for clinicians at some centers to prescribe even lower doses such as a fixed dose of 1000 mg twice daily for 14 out of 21 days.
33
Recently, there has been increasing awareness of interethnic heterogeneity in the tolerability of various drugs. The risk of serious toxic effects from fluoropyrimidines is significantly lower among East Asians compared with white patients.
9,11,34 In fact, Asian patients with the 3R/3R genotype of the thymidylate synthase gene enhancer region (TSER) were able to tolerate capecitabine up to 1500 mg/m 2 on a twice daily 2-week on and 1-week off schedule in a recent phase 1 study. 10 The genetic polymorphisms previously reported to be associated with fluoropyrimidine toxic effects (variants in DPYD, TYMS, DPYS, CDA, and MTHFR) are generally uncommon 11, 35 and exist at even lower frequencies in Asian populations (eTable 2 in Supplement 2). This may explain the very low frequency of grade 3 or 4 diarrhea, stomatitis, and neutropenia in our study, although grade 2 or higher HFS still occurred in more than 30% of patients. The etiology and predisposing factors for HFS may be distinct from other toxic effects with capecitabine. A feature of this study was the GWAS performed using arrays enriched in East Asian genotypes to explore genetic factors associated with capecitabine-related HFS. Previous studies on capecitabine-related HFS have either examined a limited number of known candidates, and/or focused on white patientbased populations. 35, 36 These studies have found specific variants in DYPD, TYMS and ENOSF1, a gene adjacent to TYMS,to be associated with overall toxic effects from capecitabine.
35,36
From our study, a number of variants were identified with plausible involvement in HFS; rs117876855, rs139544515, and 3 other variant positions of SPRY2 were in complete linkage disequilibrium, and potentially alter a total of 35 regulatory motifs. In murine models, SPRY2 acts as a negative feedback regulator of fibroblast growth factor signaling in dermal tissue 14 and functions to down-regulate angiogenesis in injured skin. 15 In addition, rs148221738 of MACF1 was assigned a ), a gene that has been strongly implicated in fluoropyrimidine toxic effects. [35] [36] [37] [38] Future functional studies and independent validation will help to ascertain whether these variants will be useful predictors of HFS risk.
Limitations
Limitations include the varying doses of capecitabine used in the study as discussed earlier, as well as termination of the trial before reaching the original accrual target. Given the relatively small sample size for GWAS analysis, these results are hypothesis-generating and will benefit from future validation in larger cohorts.
Conclusions
Our randomized, controlled phase 3 trial does not support the administration of pyridoxine to prevent HFS. We confirmed the predictive value of serum and red blood cell folate for risk of developing HFS, and identified candidate genetic polymorphisms that potentially underlie the pharmacoethnicity of capecitabine-induced HFS in an exploratory GWAS. This study highlights the value of incorporating correlative biomarkers in supportive care studies in order to improve the understanding of the pathophysiology and the risk factors of treatmentrelated adverse events. T r e a t m e n t P l a n 7 60
Study There is less data on the incidence of HFS with capecitabine and 192 oxaliplatin combination therapy, but phase two studies suggest similar or slightly lower 193 incidence of HFS with the slightly lower dose of capecitabine. Mild cases can be treated with 211 topical emollients and wound care. The rationale for using pyridoxine (vitamin B6) in HFS 212 came from the diagnosis of a similarly appearing skin disease in pyridoxine depleted rats.
213
Pyridoxine is a water-soluble vitamin which is present in foods such as red meat, bananas, 214 beans and cereals. It is involved in amino acid metabolism, and also in carbohydrate and lipid 215 metabolism. In vivo, pyridoxine is converted mainly to pyridoxal 5'-phosphate which is the 216 active coenzyme in a number of metabolic transformations, including the conversion of 217 tryptophan to niacin or serotonin, the breakdown of glycogen to glucose-1-phosphate, the 218 conversion of oxalate to glycine, the synthesis of gamma-aminobutyric acid (GABA) within 219 the central nervous system (CNS) and the synthesis of heme. In adults, pyridoxine deficiency 220 mainly affects the peripheral nerves, skin, mucous membranes and the haemopoietic 221 system.
18
There are no postulated mechanisms on how the vitamin may reverse the symptoms 222 of HFS, but there are published reports documenting its efficacy. Based on the limited data above, many patients who develop HFS on capecitabine receive 258 pyridoxine in addition to dose interruption or reduction. There are also clinicians who 259 empirically prescribe upfront pyridoxine for patients commencing capecitabine as primary 260 prophylaxis for HFS. Given that the use of capecitabine is set to increase, there is a need for 261 well-designed prospective controlled trials to investigate the role of pyridoxine in both 262 primary and secondary prophylaxis of HFS. 263 264
If pyridoxine is proven to be effective in preventing HFS, there will be less dose disruption 265 and reduction, and the efficacy of the treatment may be maintained. Patient's quality of life 266 will also improve. If the findings from the study are negative, this should lead to a change in 267 clinical practice worldwide and result in cost savings. • Signed informed consent7
• Male or female patients, age ≥ 18 years 279
• Life expectancy greater than 12 weeks. 280 (Concomitant radiotherapy, steroids or biological therapy eg trastuzumab, bevacizumab 281 permitted, as long as they do not cause HFS or neuropathy.) 282 283
Exclusion criteria 284
• Prior capecitabine chemotherapy 285
• Inability to provide informed consent 286
• Concomitant administration of drugs that can cause HFS eg docetaxel, liposomal 287 doxorubicin 288
• Concomitant administration of drugs that can cause neuropathy eg oxaliplatin, taxanes 289
• Pre-existing neuropathy confounding assessment of HFS 290
• Consumption of pyridoxine-containing preparations eg multivitamins, Vitamin B 291 complex 292
• Anticipated inability to follow-up patient for side-effects of chemotherapy 293
• Other dermatologic condition, that, in the opinion of the physician, may affect the hands 294 or feet or may complicate evaluation during study treatment 295
• Concurrent or planned use of over-the-counter products that contain urea or lactic acid eg • Known allergy to pyridoxine and its incipients 301
• Concomitant administration of drugs reported to have drug interactions with pyridoxine 302 (including cycloserine, hydralazine, immunosuppressants, isoniazid, levodopa, 303 oestrogen or oestrogen-containing contraceptives, penicillamine, phenobarbitone, 304 phenytoin, pyrazinamide) 305 306
Patients will be asked to report and/or bring all concurrent medications, over-the-counter 307 preparations and topical applications which will be checked by the treating doctor and trial 308 nurses before entering the study. They will also be reminded of the need to avoid these 309 preparations at each visit. 310
Reasons for non-entry of potentially eligible patients will also be collected in a screening log 311 (appendix 20.5). The screening log may identify factors that steered patients away from the 312 trial, dissuaded physicians or investigators from entering patients into the trial, and will help 313 assess the generalisability of the findings. The log will not contain any details that can 314 identify patients. 315 316 317
STUDY DESIGN 318 319
Randomized double-blind placebo-controlled study 320 321
Treatment Plan 322
Patients commencing capecitabine at a dose of at least 1000mg/m 2 twice daily every 2 out of 323 3 weeks will be randomized to receive either concomitant pyridoxine (200mg) or placebo 324 once daily orally for 21 days out of each treatment cycle. In the event that the patient cannot 325 start capecitabine together with pyridoxine or placebo immediately after informed consent 326 was obtained, a maximum dose delay of not more than 4 weeks is allowed. 327 328 8 329
Study duration 330
• Until grade ≥2 HFS occurs, or 331
• Until capecitabine is ceased (due to disease progression, side effects or other reason), or 332
• For a maximum duration of 8 cycles (approximately 24 weeks). 333 334 335 6.
OUTCOMES AND MEASURES 336 337
The primary outcome is the first incidence of grade 2 or greater HFS. The severity of HFS 338 will be graded 1 to 3 according to the National Cancer Institute (NCI) Common The secondary outcome of time to onset of grade 2 or greater HFS will be evaluated in days. 348 QOL will be assessed using EuroQOL EQ-5D questionnaire (attached in appendix cancers including CRC. An 8ml sample of blood will be collected from each patient at the 418 same time as routine blood draw using cell preparation tube (CPT) at baseline. 419
The sample will be identified by the study number with no direct identification of the patient 420 from the sample. DNA will be extracted using standardised methods and stored at minus 20 421 degree celsius for subsequent genotyping at Dr. Richie Soong's laboratory. 422
Genotyping for polymorphisms of putative relevance to pyridoxine and capecitabine 423 metabolism (especially thymidylate synthase, thymidine phosphorylase, dihydropyrimidine 424 dehydrogenase, cytidine deaminase, carboxylesterase, methyltetrahydrofolate reductase) will 425 be performed using previously described techniques. 426
Additional 10ml of blood will also be taken for baseline serum and red cell folate and 427 vitamin B12 levels. 428 429
The incidence rate of the gene polymorphisms will be summarised and evaluated. The null hypothesis of this study is that concomitant pyridoxine does not reduce the risk of 458 developing grade ≥2 HFS. The alternative hypothesis is that concomitant pyridoxine reduces 459 the risk of grade ≥2 HFS. 460 461
The overall incidence of grade ≥2 HFS for capecitabine single-agent cytotoxic therapy is 462 estimated to be 36-40%. Pyridoxine prophylaxis will be clinically worthwhile if it can almost 463 halve the incidence of grade ≥2 HFS. 464 465
To detect a reduction in the incidence of HFS from 36% to 20% with upfront pyridoxine at a 466 power of 80%, 123 patients per group will be required. We anticipate that up to 20% of the 467 patients may cease capecitabine before 4 cycles due to reasons such as disease progression 468 and intolerance of other side-effects. To make up for the difficulty in evaluating HFS in these 469 12 patients, we intend to recruit extra 20% or 25 patients in each arm. Hence the target accrual 470 will be 296 patients in total with 148 patients for each arm. The study will be monitored at regular intervals. Study procedures and study-related 556 toxicities will be monitored by the principal investigator and any study-related problems will 557 be evaluated and discussed with the investigators. 558 559
Patient Identification 560
All patients screened for the study will have their initials and birth date recorded. If a patient 561 is excluded from the study, the reason is to be documented in a screening log. The 562 investigator will be assigned a block of consecutive patient allocation numbers. Eligible 563 patients entering the study will be assigned a patient allocation number sequentially 564 beginning at the top of the allocation number list. The patient allocation number and patient's 565 initials are to be entered on all case report forms. 566 567 568 569
Data Handling 570
Each patient's data will be kept in individual files (case report forms). Data will be collected 571 by oncology research nurses and data managers. All data, protocols, amendments, 572 authorisations and correspondence will be stored at the trial centre(s). All data will be kept in 573 coded form and information will remain confidential. All data collection will be monitored to 574 ensure thorough and accurate collection. 575 576
Recording of Data 577
Case report forms (CRF) must be typewritten or printed legibly. The forms will be verified 578 against original records (and workbooks, if applicable). CRFs and all original data will be 579 readily available for review. 580 581
Record Retention 582
Copies of all pertinent information will be retained by the investigator for a period of 15 583 years following the date of study completion. 584 585 586
16.
ETHICAL CONSIDERATIONS 587 588
Although pyridoxine is frequently used in the treatment or prevention of HFS from 589 capecitabine, the evidence is limited to mainly retrospective observational studies so far. 590
Pyridoxine, being a type of vitamin, rarely causes any side effects at the dosage used in this 591 study. This double-blind placebo-controlled trial will evaluate w h e t h e r c o n c o m i t a n t 592 pyridoxine can significantly prevent grade 2 or greater HFS in patients receiving 593
capecitabine. 594 595
Ethical Conduct of the Trial 596
The trial will be performed in accordance with the recommendations guiding physicians in 597 biomedical research involving human patients adopted by the 18th World Medical Assembly, 598
Helsinki, Finland, 1964 and later revisions. 599 600
Centralized Institutional Review Board (CIRB) 601
It is the responsibility of the investigator to obtain approval of the trial protocol and any 602 amendments of the protocol from the CIRB. The final approved protocol and the patient 603 information sheet and informed consent statement to be administered will be reviewed by the 604 CIRB. The Board's decision concerning conduct of the study will be made in writing to the 605 investigator. All correspondence with the CIRB should be filed by the investigator. The study 606
shall not commence until the CIRB has approved the study. 607 608
Patient Information and Consent 609
It is the responsibility of the investigator to give each patient (or the patient's acceptable 610 representative) prior to inclusion in the trial, full and adequate verbal and written information 611 regarding the objective and procedures of the trial and the possible risks involved. The 612 patients must be informed about their right to withdraw from the trial at any time. A CIRB 613 approved written patient information sheet (included as an appendix to the protocol) must be 614
given to each patient before enrolment. An approved informed consent statement will then be 615 read and signed by the patient and the investigator. The written patient information must not 616 be changed without prior approval by the CIRB. Furthermore, it is the responsibility of the 617 investigator to obtain signed informed consent from all patients prior to inclusion in the trial. 618 619 relatively low doses (50 mg/day). Neuropathic symptoms generally subside after the 821 withdrawal of pyridoxine. 822
Following the administration of pyridoxine in the treatment of seizures in neonates, severe 823 sedation and respiratory distress have been reported. Therefore, it is recommended that 824 resuscitation facilities be available when pyridoxine is given in these circumstances. 
